Form 4: Director Jean-Francois Formela Sells Korro Bio Shares

Director Jean-Francois Formela sold 2,860 shares of Korro Bio, Inc. common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Director Jean-Francois Formela sold a total of 2,860 shares of Korro Bio, Inc. (KRRO) on May 28, 2026.
• The shares were sold at a price of $13.95 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on April 8, 2026.
• The shares sold were held indirectly through Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement, which is a standard administrative action for venture capital firms.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without concerns regarding non-public information.

Negatives

• Insider selling can sometimes be perceived by the market as a lack of confidence in the short-term price appreciation of the stock.

Risks

• The reporting person maintains significant indirect ownership, meaning future divestments by the associated venture funds could impact market liquidity or sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is common practice for venture capital partners managing fund distributions and does not necessarily reflect a change in the company's fundamental outlook.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to manage equity holdings while maintaining compliance with SEC regulations.

Related Party Transactions

• The reporting person is a member of the general partner entities for Atlas Venture Fund XI, L.P. and Atlas Venture Opportunity Fund II, L.P.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the total holdings.

Next Steps

• Continued monitoring of future Form 4 filings for further divestment activity by the reporting person or associated funds.

Key Dates

Keywords

Korro Bio, KRRO, Insider Trading, Form 4, Biotech, Atlas Venture